Biomedex held a gala open house on Feb. 22 to report on its progress in several ventures. Aside from its development plans and its main focus on helping startups, Biomedex will seek other biotech and biomedical opportunities, including acting as a distributor of medical devices, according to President George M. Coleman . Corixa announced results for the fourth quarter and year ended Dec. 31, 2000. The increase was primarily attributable to revenue recognized from collaborative agreements with GlaxoSmithKline, Japan Tobacco's pharmaceutical division, Medicis Pharmaceutical, and Purdue Pharma. Endpoint is the new name of International Drug Development Consulting, a long-time WBBA member.
Endpoint provides advice on the clinical development of medicines.
Clients include multinational pharmaceutical companies, contract research organizations, emerging biomedical companies, biotechnology investment firms, regulatory agencies and national health services. Immunex announced key personnel moves as part of its long-term strategic plan. Cohen-Arazi joined Immunex as Senior Vice President of supply operations, Michael Aguiar is the new VP of Finance, and Deborah Helleson was promoted to VP of business development. Immunex also said it will make presentations at several investor conferences in this month, including the US Bancorp Piper Jaffray Pacific NW Investor Conference on March 9 in Seattle. Institute for Systems Biology will move from its offices in the University District of Seattle into a new headquarters near Gasworks Park on the north side of Lake Union later this year.